Compare Phillips 66 (PSX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Spyre Therapeutics Inc. Common Stock — how do they compare? Phillips 66 trades at $298.06 (market cap $116.81B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Phillips 66 is far larger — about 15.5× Spyre Therapeutics Inc. Common Stock's market cap, and Phillips 66 pays a 1.74% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 63 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PSX | SYRE | |
|---|---|---|
Market Cap | $116.81B | $7.52B |
Volume | 2,609,145 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $297.29 | $108.92 |
52-Week Low | $127.75 | $22.18 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $133.27B | $6.52B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $292.73, up 4.0% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with recent earnings beats, including Q2 2026 EPS of $9.41 versus $7.50 expected, and attractive valuation metrics with P/E of 16.71 and P/S of 0.78. Refining margins remain elevated, supported by structural capacity gaps, while the company maintains solid profitability with 24.02% ROE.
PSX presents a compelling investment case with analyst consensus leaning bullish (54% Buy ratings) and a price target of $286.90. Key risks include potential diesel export policy changes and cyclical refining margin compression. The upcoming Q3 2026 earnings report on October 28, 2026, will be critical for validating the current positive momentum and structural earnings thesis.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
